1. Home
  2. ACON vs GNPX Comparison

ACON vs GNPX Comparison

Compare ACON & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclarion Inc.

ACON

Aclarion Inc.

BUY

Current Price

$5.27

Market Cap

4.4M

Sector

Technology

ML Signal

BUY

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.92

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACON
GNPX
Founded
2008
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.2M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
ACON
GNPX
Price
$5.27
$1.92
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
104.5K
194.3K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,483.00
N/A
Revenue This Year
$71.77
N/A
Revenue Next Year
$80.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.91
N/A
52 Week Low
$4.32
$1.71
52 Week High
$2,156.31
$55.00

Technical Indicators

Market Signals
Indicator
ACON
GNPX
Relative Strength Index (RSI) 42.79 36.17
Support Level $4.32 $1.71
Resistance Level $6.40 $1.88
Average True Range (ATR) 0.40 0.16
MACD -0.05 0.01
Stochastic Oscillator 45.79 23.62

Price Performance

Historical Comparison
ACON
GNPX

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: